VC Fund Dossiers

DCM is a solid, no-nonsense shop that actually helps you scale internationally if that's your thing. They're particularly strong if you're building B2B software and want access to Asian markets - their network there is legit. Jason Krikorian is sharp on product strategy and won't sugarcoat feedback. The downside? They're not the flashiest name on your cap table, and their marketing game is pretty weak compared to peers. They tend to be methodical rather than aggressive, which is great for steady builders but might frustrate founders who want rapid-fire decision making.

Dcode is the real deal if you're selling to the government - they actually understand the byzantine federal procurement process and have the relationships to help you navigate it. Unlike most VCs who talk a big game about GovTech, these folks have actually done it. The downside? They're laser-focused on dual-use, so if your tech doesn't have clear government applications, look elsewhere. They're also smaller than the big-name funds, so don't expect huge follow-on rounds. But if you're in cybersecurity, data analytics, or infrastructure with government potential, they're genuinely helpful and connected.

DCVC is the rare fund that actually understands deep tech beyond the buzzwords — these guys can evaluate your algorithm and your go-to-market strategy with equal sophistication. They're genuinely helpful post-investment, especially if you're navigating complex enterprise sales cycles or regulatory approval processes. The downside? They have very high technical bars and can be slow to move if they're not immediately convinced of your computational moat. Don't pitch them unless you have serious IP or algorithmic differentiation — they'll smell BS from a mile away.

Debut is one of the more founder-friendly shops in the ecosystem - they actually mean it when they say they back founders, not just ideas. Ezra and the team are known for rolling up their sleeves and helping with real operational stuff, not just writing checks and showing up to board meetings. They've had some solid wins with Ramp and others, which gives them credibility. The Brooklyn base is refreshing - less Silicon Valley groupthink, more scrappy East Coast hustle. They're still relatively small so you'll get real attention, but that also means limited dry powder for follow-ons compared to the mega-funds.

Decibel is a solid, no-nonsense B2B fund that actually knows what they're talking about in enterprise software. The partners have real operating experience and don't just throw around buzzwords. They're particularly strong in helping technical founders figure out go-to-market, which is rare. The downside is they're not huge brand names, so you won't get the same signaling value as a top-tier fund. But if you're building in their wheelhouse and want investors who roll up their sleeves, they're worth taking seriously.

Decisive Point is the fund you want if you're building for government or heavily regulated markets — they actually understand these sales cycles and have the relationships to help. Schroeder and Janke bring real operational experience, not just check-writing credentials. The downside? Their portfolio focus is narrow, so if you're building consumer or traditional SaaS, look elsewhere. They're also relatively small, so don't expect the brand recognition or downstream fundraising pull of a tier-one fund. But for the right founder in their wheelhouse, they punch above their weight on value-add.

Deerfield is the definition of a healthcare heavyweight — one of the largest dedicated healthcare funds globally with serious operational chops. Flynn has built something genuinely differentiated: they don't just write checks, they roll up their sleeves with in-house R&D (3DC), their own innovation campus (Cure), and deep academic partnerships. The good news? They're genuinely helpful post-investment and know how to navigate complex healthcare deals. The elephant in the room? The 2017 insider trading scandal that led to $4.6M in SEC fines and prison time for two partners (later overturned on appeal). While Flynn himself wasn't implicated and the firm has clearly moved past it, it's a reminder that even top-tier firms can have compliance blind spots.

Define Ventures has quietly become the healthcare VC kingmaker you didn't know you needed to know about. With $800M AUM, they're now one of the largest early-stage health tech funds, but what makes them special isn't size—it's their operator-heavy bench. They just landed Bruce Broussard (12-year Humana CEO) and Frank Williams (Evolent founder) as venture partners, giving founders direct access to Fortune 50 healthcare executives who've actually run the systems they're trying to disrupt. The proof is in the pudding: 72% of their portfolio companies have customers within their coalition of leading healthcare organizations—that's not luck, that's systematic customer development. Founders rave about their hands-on approach, with testimonials mentioning they "drive shareholder value in a step function manner" and provide "strategic connections throughout the industry." The downside? They're getting picky as they scale, and their growing brand means more competition for their attention.

Defy is what happens when two heavy-hitting ex-partners from Kleiner and General Catalyst decide to build their own sandbox - and they've done it right. Their 'Sage' program is legitimately differentiated: they give serial founders like Brian Lee (LegalZoom, Honest Co.) and Sujal Patel (Isilon sold for $2.5B) actual fund-level carry to roll up their sleeves with portfolio companies. This isn't token advisory work - these operators sometimes take interim leadership roles and personally help raise follow-on rounds. Neil and Trae have strong track records and the discipline to stay 'right-sized' rather than chase AUM growth like everyone else. The downside? With $400M+ AUM across two funds and a small team, they're selective as hell and you better have serious traction before they'll take a meeting.

Denver Ventures launched in 2025 from Denver Angels with over $60M AUM, focusing on 'Founder DNA' - their buzzwordy but seemingly genuine approach to identifying exceptional entrepreneurs. They've brought in Martin Dubin, a clinical psychologist who consulted with A16z for a decade, adding scientific methodology to founder assessment beyond 'gut instinct.' The fund has solid credibility - David Prichard ran Access Ventures for 11+ years and Amy Brandenburg has real operational chops from GitLab's IPO. Their portfolio company Urban Sky calls them 'founder-friendly, supportive when you need it, and knowledgeable' - which is exactly what you want to hear, not the typical VC fluff. They've built one of the nation's largest investor networks through Denver Angels with 800+ family offices and HNW individuals, giving real connectivity power.

This isn't your typical Silicon Valley VC - Desjardins Capital is the venture arm of a massive Quebec credit union with a mandate for regional economic development. That means they're patient, risk-averse, and focused on sustainable businesses rather than moonshot bets. The upside is genuine strategic support and no pressure to flip quickly. The downside is they're very Quebec-centric and may not have the risk appetite or network for truly disruptive plays. They're solid operators but think more like a family office than a high-growth fund. If you're building a sustainable business in Quebec, they're goldilocks capital. If you're trying to build the next unicorn, look elsewhere.

DVP is basically Dan Gilbert's personal mission to rebuild Detroit through tech, and that comes with both massive upside and some quirks. The Rock Family of Companies connection is real value - you get access to Rocket Mortgage's customer base, Cleveland Cavaliers marketing deals, and Gilbert's real estate empire. But here's the thing: Five years after being founded by Dan Gilbert, Josh Linkner and Brian Hermelin as a way to invest in early-stage technology companies, DVP is yet to have any big wins. Meanwhile leadership has been in flux, there have been layoffs at several portfolio companies, and some founders abandoning Detroit for the fertile grounds of San Francisco. StockX was their home run, but that took years to materialize. The fund went through growing pains in the mid-2010s with founder departures and portfolio struggles. Current leadership under Cohen and Stasik seems more stable, and they've been active with In 2025, it made 3 investments. The Detroit-first mandate can be limiting if you're not local, but if you are building something that fits their ecosystem, the strategic value is legit.

Diagram isn't your typical VC - they're basically a startup factory with deep pockets and McKinsey-level process discipline. Francois runs a tight ship with genuine operator credibility (Stanford MBA, McKinsey alum, multiple exits), which shows in their portfolio quality. The Sagard backing gives them serious capital firepower and corporate connections that most Montreal funds can't match. But here's the thing: their venture builder model means they're incredibly hands-on early but potentially more controlling than traditional VCs. Founders love the operational support (accounting, HR, legal all handled) but some find the 'validated idea first, then find founder' approach limiting if you have your own vision. They're phenomenal if you want a proven playbook and serious support infrastructure, but not ideal if you're looking for a hands-off partner who just writes checks.

Here's the uncomfortable truth: Discovery Capital is essentially a zombie fund. Their main vehicle, BC Discovery Fund, is in voluntary liquidation with shareholders having approved the windup, and their website shows an 'under construction' page. While they claim big exits like Spotify and Cardlytics, the reality is their remaining portfolio company Phemi has 'no possibility of material realization' with debts exceeding assets. The founders have decades of experience and genuine relationships in the Canadian tech scene, but this isn't an active fund you can realistically pitch - it's winding down operations and liquidating assets.

Disruption Ventures plans to make initial investments with the $13 million, with plans to continue fundraising to reach its $30 million funding goal in 2019. Reaching that goal would make it the largest private, independent, and women-only led fund in Canada, according to Scotiabank. Elaine Kunda is the real deal - she's not just another GP who stumbled into VC from consulting or banking. She's built and sold companies, which means she actually understands the founder journey. I sincerely enjoy her coaching & how she consistently challenges my thinking. Her honesty & candor are making me a better leader, & she truly walks the talk when it comes to accelerating women-led businesses. The portfolio is decent but not spectacular - mostly solid B2B SaaS plays rather than moonshots. The fund size is small which can be both good (more attention per company) and bad (limited follow-on capital). They're operationally focused which founders seem to appreciate, though the women-only mandate obviously limits their deal flow significantly.

Dolby Family Ventures is the real deal - a single family office that actually operates like a proper institutional fund, not some rich family's pet project. As a family organization, they can make 'Yes-or-no' decisions much faster than many large VC funds, which is a genuine competitive advantage. Pascal Levensohn brings serious pedigree from decades of venture investing, while David Dolby's technical background and direct connection to the Dolby legacy gives them credibility with deep-tech founders. Their laser focus on neurodegeneration isn't just marketing - it's personal mission work with serious capital behind it. The red flag? They backed Athira Pharma, which paid a $4 million settlement in 2025 for CEO research misconduct allegations - though this reflects more on due diligence challenges in biotech than fund quality.

This isn't really a VC fund in the traditional sense - it's Dow Chemical's strategic checkbook with a venture capital facade. They've made 117 investments since 1994, but every single deal has to somehow benefit Dow's massive industrial empire. Think of them as corporate development with extra steps. The upside? They bring real industrial expertise, manufacturing scale, and can actually help you commercialize hard tech that requires serious operational know-how. The downside? Your startup better align perfectly with Dow's strategic priorities, or you're not even getting a meeting. They're not chasing unicorns or market returns like traditional VCs - they're shopping for technologies that make Dow's chemicals business more competitive.

Tim Draper is venture capital's ultimate contrarian cheerleader — he'll bet on your "impossible" idea when everyone else thinks you're insane, but comes with some baggage founders need to know about. He was one of the first investors in Theranos and continued defending Elizabeth Holmes even after SEC fraud charges, saying she had been 'bullied into submission.' That's classic Tim — loyal to a fault, sometimes blind to red flags. Founders love that he "never refused to look at my business plan or answer a question, and nearly always replied in almost real-time," but he operates more like an enthusiastic startup evangelist than a traditional VC. He's literally using AI "digital twins" to scale founder meetings and has entrepreneurs talk to his hologram at Draper University. The guy runs a TV pitch show, an entrepreneur bootcamp, and manages to stay genuinely excited about every wild idea that crosses his desk. If you want a VC who'll believe in your moonshot and give you the "go big or go home" mentality, Tim's your guy — just don't expect traditional institutional discipline or governance.

This is old-school Midwest VC at its most authentic - no Silicon Valley posturing, just solid operators who've been grinding in Pittsburgh since 1999. With $200 million under management across three funds, they're not trying to be the biggest check in the room, but they've got one unicorn (Ivalua) and 19 exits including recent acquisition of Aware by Mimecast. The partners actually have operating experience - Stubler built and sold a company, Katarincic did M&A at a white-shoe law firm. They're genuinely hands-on and will roll up sleeves, but don't expect cutting-edge social media presence or trendy investment themes. Haven't made any investments in 2025 and average only one new investment annually over the last decade, suggesting they're either very selective or potentially winding down activity.

Drive takes massive ownership stakes - around 30% on average versus typical Valley 10% - and in 20% of their portfolio, they're the sole venture investor across all rounds. Olsen runs a deliberately contrarian strategy targeting realistic $3B exits rather than chasing unicorns, which actually works better for returns. They've had spectacular failures (Olive AI raised $900M at $4B valuation before fire sale) but also massive wins (Duolingo at $18B market cap). The 2022 co-founder split created internal drama but may have strengthened the firm under Olsen's focused leadership. Founders outside Silicon Valley "have a higher bar" and "have to be a better business to earn a venture investment" - so if you're not coastal, they actually get you.

These folks are the real deal in supply chain investing — they're the country's only logistics technology venture capital fund and have grown from an idea into one of the largest venture funds in the Southeast. Kline Hill Partners bought a significant stake in Fund I creating returns over 4x and signaling strong conviction in Dynamo's portfolio, with overall performance placing the fund in the top decile of its vintage. The operator backgrounds are legit — Ted Alling and Barry Large built a logistics company that sold to UPS for $1.8B, so they actually know this space inside and out. They promise speed and clarity, claiming they can move from first meeting to term sheet in four weeks or less. The downside? If a business does not check one of these boxes they are not the right investors for you. Given the background of the fund's founders, the company will always be slightly more biased towards the supply chain — so if you're not squarely in their wheelhouse, don't waste your time.

Eclipse isn't just another hardware fund — they're ex-operators who actually know what it takes to scale physical businesses. Greg Reichow literally built Tesla's manufacturing from scratch, and Lior survived the trenches at Flex before starting Eclipse. They don't just write checks; founders consistently praise them as 'true co-founders' who provide deep industry access and operational guidance. Their $1.2B Fund V shows they have serious firepower, but the real differentiator is their willingness to lead large rounds ($350M in Redwood Materials) and stick with companies through multiple follow-ons. The downside? They're picky as hell and focused on a narrow thesis, so if you're not solving a massive physical industry problem with serious technical moats, don't bother.

EcoR1 is essentially Oleg Nodelman's biotech hedge fund masquerading as a VC firm, and that's both its strength and potential weakness. Managing over $5 billion in discretionary assets, Nodelman brings serious biotech expertise from his BVF days and sits on multiple public biotech boards. The fund clearly knows how to pick winners and has impressive returns. But don't expect traditional VC hand-holding—this is more financial engineering than startup nurturing. They're great if you need smart money that understands biotech deeply, but if you want a partner who will roll up their sleeves on board management and recruiting, look elsewhere. Their portfolio skews heavily toward later-stage, publicly traded companies, so early-stage founders should manage expectations accordingly.

Edison is what growth equity looked like before everyone went insane with valuations and spray-and-pray tactics. They call themselves 'old-school' and disciplined, focusing on 'thoughtful, high growth, but not growth at all costs.' The Edison Edge platform isn't just marketing fluff — founders actually rave about it, with more than 90% of portfolio companies actively engaged and averaging 70-80% annual revenue growth. Being named to Inc.'s Founder-Friendly list for five straight years isn't an accident — they genuinely seem to care about operators over financial engineering. The catch? They're picky as hell and focus outside Silicon Valley, so if you're not in their sweet spot of $10-30M revenue fintech/healthcare/enterprise software, don't waste their time.

This is a solid, if unremarkable, growth-stage fund with impressive exits under their belt. Hunt's Warby Parker pedigree gives them serious founder credibility, and their KnowBe4 investment (early Series A that rode to a $4.6B Vista exit) shows they can spot enterprise winners early. The Highland Capital background means they know how to do proper diligence and aren't chasing shiny objects. That said, they're not particularly innovative or thesis-driven - more like competent capital allocators who write decent checks. Their recent investments suggest they're sticking to their knitting: boring but profitable enterprise software plays. If you're a Series A/B SaaS founder looking for experienced operators who won't micromanage, they're worth a conversation.

Here's the thing - there's no 'Elevance Health Ventures' VC fund. You're looking at a $177B health insurance giant that deploys capital very differently than traditional VCs. They write massive checks for strategic acquisitions and partnerships (like their $4B primary care venture with PE firm Clayton Dubilier & Rice), not seed rounds for health tech startups. Their 'venture' activity is really corporate development on steroids - they buy established healthcare companies to vertically integrate their insurance business. If you're a startup founder looking for venture capital, this isn't your fund. But if you're a later-stage healthcare services company looking for a strategic acquirer with deep pockets and 119 million covered lives, now we're talking.

This is one of the few diversity-focused funds that actually delivers returns - Fund I has returned 125% of invested capital with a 22% IRR, putting it just shy of top quartile performance for 2016 vintage funds under $100M. Nitin Rai gets genuinely hands-on as an immigrant entrepreneur himself, and founders consistently praise his deep engagement beyond just board meetings. The Oregon ecosystem has its challenges - the state attracts 10x less capital than Washington despite having half the population, and recent IPO disasters like Vacasa and Expensify haven't helped the region's reputation. But Elevate's thesis is working: over 62% of their Fund II investments were women-led, 67% founders of color, and they're genuinely creating access where traditional VCs won't go. The public-private partnership model with Oregon gives them patient capital that most VCs don't have, letting them take bigger bets on underrepresented founders.

Elevate is the scrappy state champion that punches above its weight class—they're legitimately the #1 most active early-stage VC in the Great Lakes and crack the top 10 nationally despite being based in Indianapolis. But here's the reality check: they're essentially a government-backed fund masquerading as private VC. In 2025, they got slapped with breach notices from the Indiana Economic Development Corp after defaulting on loan agreements, though a forensic audit later cleared them of illegal activity. The returns are underwhelming—their first fund achieved just a 1.24x MOIC with their overall portfolio at 1.2x. Toph Day is a genuine entrepreneur who built real companies, but founders should know this isn't coastal VC money—it's public dollars with political strings attached.

Elsewhere is what happens when seasoned Austin Ventures alumni decide to fish in less crowded waters — and it's working brilliantly. Chris Pacitti figured out that bootstrapped software companies outside the coasts are getting ignored by traditional VCs but are often better businesses with real revenue and customers. The operating advisor network is legit (former SolarWinds and ActivTrak execs), not just brand names collecting board fees. They're basically doing growth PE at Series A scale, which is smart positioning. The downside? With John Thornton's passing and the firm scaling rapidly, there's execution risk. Also, their "majority control" approach might spook founders used to minority VC deals, even though the testimonials suggest they're founder-friendly.

Embark is a competent but quiet deep tech fund that actually knows what they're doing in robotics and industrial automation. They're one of the very few deep tech/frontier tech focused investors in LA, writing $500K-$1M checks into pre-product companies with important science behind them. Their portfolio companies like Machina Labs ($124M Series C) and SafeAI (acquired by Pronto AI) show they can spot real technical defensibility and help companies scale. The partners have solid backgrounds - Peter from McKinsey and traditional VC, Yipeng with quantitative chops from UCSD. They don't chase hype cycles or make noise on Twitter, which in today's market actually makes them more appealing to serious technical founders who want investors who understand their tech stack.

Each partner makes just one investment annually and the whole team works on every deal - this isn't marketing fluff, it's their actual model and they have zero partner turnover with sustained support throughout your journey. The founder testimonials are unusually specific and glowing, suggesting they actually deliver on the white-glove treatment. Eric Yuan calls them 'family' and says they were Zoom's first Silicon Valley institutional investor. However, their selectivity is real - only 5-7 deals per year means you're competing against the entire enterprise software universe for their attention. Co-founder Jason Green stepped back in 2021 after 30 years, so you're working with the next generation, though Gordon Ritter is still very active and made Forbes Midas List four times.

Emergence Capital is the definition of conviction-driven investing—they've mastered the art of going all-in on a tiny number of bets and hitting home runs. Their one-investment-per-partner-per-year model isn't marketing fluff; it's real, and founders feel the difference. The Zoom and Veeva wins created generational wealth and cemented their reputation as B2B SaaS kingmakers. What's impressive is their zero partner turnover culture and internal promotion track record—Jake Saper and Santi Subotovsky both worked their way up, creating genuine institutional knowledge. They're obsessed with AI-enabled services and 'deep collaboration' themes, sometimes to a fault—they can get thesis-heavy and miss opportunities outside their framework. Post-investment, they're genuinely helpful operators who understand enterprise sales motions and hiring, not just check-writers.

This isn't your typical VC fund - it's Laurene Powell Jobs' $28B family office that can write $500M checks and literally owns The Atlantic magazine. They operate as a "deliberately flexible LLC that combines venture capital, philanthropy, advocacy, art, and media ownership under one roof" and can use "whatever tool is most effective for a given problem rather than being constrained by traditional fund structures". The upside: they have patient capital, can support you beyond just money (grants, policy advocacy, media amplification), and maintain a low-profile public approach but are highly accessible and emphasize founder relationships over press coverage. The reality check: Powell Jobs' philanthropy has been described as having limited "transparency and accountability," and you need to genuinely care about social impact - this isn't just marketing speak for them.

These guys actually get it - they start with the problem, not the technology, because 'if you're too early in climate, you lose all your money.' John Tough's background as employee #3 at Choose Energy gives them real operator credibility, and their Invenergy anchor LP provides unmatched industry access to Fortune 2000 energy companies within 100 miles of Chicago. Their track record speaks volumes: one unicorn (Aurora Solar), six exits including Urbint's $325M sale to Itron, and Nozomi's acquisition by Mitsubishi Electric - the largest OT/IoT acquisition in history. What sets them apart is their Energize EDGE platform - 25% of their firm headcount focused on value creation, completing 150+ projects across their portfolio. The proof is in the pudding: their portfolio software revenue grew from $100M to nearly $400M in three years. If you're building climate software and want investors who've actually been in the trenches, these are your people.

EnerTech is the rare energy-focused fund that actually gets operationally dirty with their portfolio companies - they're not just check-writers waiting for quarterly updates. Wally Hunter famously backed a heavily tattooed founder pitching from hostels after hundreds of other VCs passed, and that founder credits EnerTech's belief and strategic guidance as pivotal to their success. The firm is known for its deep sector expertise and long-term partnerships, often working hands-on with startups to scale their businesses, with leadership bringing decades of energy innovation experience. Their strategic differentiator is deep understanding of target markets and breadth of relationships with industry incumbents, embracing continuous learning and facilitating dynamic knowledge exchange between their investment team and corporate LPs. They've had 29 acquisitions including INVIDI Technologies and Comverge, showing they can actually get companies to exit, not just grow them forever.

Engage is one of those rare finds where the gimmick actually works. Most corporate innovation 'platforms' are just marketing BS, but Engage has somehow convinced 17 Fortune 500 companies to actually write checks and do business with startups, not just shake hands at conferences. The corporate partnerships aren't just for show - they've signed over 140 real contracts with portfolio companies. Blake Patton is a true ecosystem builder who gets both the startup and corporate sides, having scaled iXL to $400M+ revenue. The $250K check won't change your life, but the corporate access absolutely might. Just know you're signing up for enterprise sales cycles, not consumer tech magic.

Eniac is what happens when four Penn engineering buddies who've actually built and sold companies decide to do VC the right way. They're true operator-investors who've maintained their partnership for 15+ years without the usual drama, which is honestly remarkable. The partners have genuine empathy for founders because they've all been there - Harris had two exits, Mehta built multiple startups, Young sold his Beijing company. They're not just writing checks; they're in the trenches helping with product-market fit, which is their obsession. The downside? They can be pretty hands-on, so if you want a passive investor who just wires money and shows up to board meetings, look elsewhere. But if you want partners who will roll up their sleeves and help you figure out the messy 0-to-1 journey, they're gold.

EPIC is Utah's OG venture shop with serious street cred - 1 unicorn, 6 IPOs and 47 acquisitions including key companies like Ancestry, Recursion Pharmaceuticals and Genpact since 1994. What sets them apart is their deep operational chops and genuine founder-first mentality. EPIC Managing Directors Kent Madsen and Nick Efstratis have both been with the firm for over 20 years. Kent, formerly the CEO of a publicly traded NASDAQ Company, has been directly involved in 6 IPO's and dozens of acquisitions. They're not just check-writers - they roll up their sleeves and actually help build companies. We are very active investors and seek board of directors representation in each of our investments. The Zions Bank backing gives them unique staying power and banking relationships that most VCs can't match. Fair warning though: they're thorough in due diligence and expect serious commitment from founders.

Rick and the Equal crew are the real deal - they actually do the homework before writing checks, publishing deep research reports on sectors before they invest rather than pattern-matching their way through meetings. One founder noted that even when Equal wasn't an investor, their questions and industry parallels unlocked new ideas to experiment with - especially valuable when working in spaces that are hard for outsiders to understand. They make unusually large $1.5M initial checks into very few companies and openly share their mistakes and failures rather than just celebrating wins. The flip side? Their thesis-driven approach means they'll pass on great companies outside their four lanes, and co-founder Richard Kerby stepped back to Venture Partner in 2024, so there's been some leadership transition.

This is what founder-friendly looks like when it's done right. With $70M+ under management from over 500 founders and operators as LPs including founders of Zillow, One Medical, Klaviyo, and dozens more, they've basically built a founder mafia as a fund. Portfolio founders consistently describe their support as 'rivaling firms ten times their size', and with portfolio companies raising follow-on from Sequoia, Benchmark, A16Z, and other top-tier firms, they clearly know how to set companies up for success. Jenny's Techstars track record speaks for itself, but the real magic is in their community-driven model where hundreds of successful founders are actively helping with deal flow, diligence, and founder support.